{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:03:36Z","timestamp":1784138616589,"version":"3.55.0"},"reference-count":97,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["831458"],"award-info":[{"award-number":["831458"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,6,17]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore differences in preferences for participation in trials with varying degrees of decentralisation among individuals with type 2 diabetes mellitus (T2DM) and to show how personal, disease specific, digital and trial experience factors influence these preferences as well as impact potential trial participation rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A discrete choice experiment was conducted, including 16 choice tasks, with each two trial options and an opt-out.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Preference data was collected in the Netherlands between July 2023 and July 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 276 individuals with T2DM aged \u226518 years took part in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Trial options comprised six attributes: contact with the study team, activities to perform yourself, use of digital technologies, number of scheduled contacts, trial duration, safety and efficacy of the drug. Preference heterogeneity was explored using a latent class analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four classes were identified displaying differences in preferences for trial designs. Younger female participants were more likely to have a strong preference for decentralised trials in any form. Two different classes of elderly participants were identified: elderly males who were more likely to accept any trial design including decentralisation versus elderly who were more likely to be averse to participation in all trials. The latter class showed an increase in participation probability for a home-based trial including video consultation, but still was not very likely to join.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Decentralisation in trials was overall preferred over site-based trials, but variation in preferences was identified and associated with age and gender. This may impact the choice for decentralisation in trials, especially since women and the elderly are often under-represented in trials. Understanding patient preferences may help to overcome participation challenges and to increase diversity in future trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-116239","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:05:53Z","timestamp":1784135153000},"page":"e116239","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Do all individuals with type 2 diabetes mellitus prefer decentralisation in clinical trials? Findings from a discrete choice experiment"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4082-0807","authenticated-orcid":false,"given":"Julia","family":"Kopanz","sequence":"first","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorien","family":"Veldwijk","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy & Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands"},{"name":"Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Lagerwaard","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-4233","authenticated-orcid":false,"given":"Julia K","family":"Mader","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Tews","sequence":"additional","affiliation":[{"name":"MVZ Diabeteszentrum Dr. Tews GmbH, Gelnhausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas T","family":"van Sloten","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine and Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederick E","family":"Grobbee","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-8243","authenticated-orcid":false,"given":"Mira G P","family":"Zuidgeest","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026071510051895000_16.7.e116239.1","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-4197-3","article-title":"Why do patients take part in research? An overview of systematic reviews of psychosocial barriers and facilitators","volume":"21","author":"Sheridan","year":"2020","journal-title":"Trials"},{"key":"2026071510051895000_16.7.e116239.2","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100829","article-title":"Barriers and facilitators to the participation of subjects in clinical trials: An overview of reviews","volume":"23","author":"Rodr\u00edguez-Torres","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"2026071510051895000_16.7.e116239.3","article-title":"Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis","volume":"10","author":"Houghton","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026071510051895000_16.7.e116239.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-022-01803-6","article-title":"How do study design features and participant characteristics influence willingness to participate in clinical trials? Results from a choice experiment","volume":"22","author":"Thomas","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"2026071510051895000_16.7.e116239.5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jpain.2016.07.008","article-title":"Participant Preferences for Pharmacologic Chronic Pain Treatment Trial Characteristics: An ACTTION Adaptive Choice-Based Conjoint Study","volume":"17","author":"Smith","year":"2016","journal-title":"J Pain"},{"key":"2026071510051895000_16.7.e116239.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036056","article-title":"Personal preferences for Personalised Trials among patients with chronic diseases: an empirical Bayesian analysis of a conjoint survey","volume":"10","author":"Cheung","year":"2020","journal-title":"BMJ Open"},{"key":"2026071510051895000_16.7.e116239.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-025-08850-6","article-title":"Why do patients take part in research? An updated overview of systematic reviews of psychosocial barriers and facilitators","volume":"26","author":"Knapp","year":"2025","journal-title":"Trials"},{"key":"2026071510051895000_16.7.e116239.8","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otz048","article-title":"Preferences of Adult Patients With Inflammatory Bowel Disease for Attributes of Clinical Trials: Evidence From a Choice-Based Conjoint Analysis","volume":"2","author":"Wood","year":"2019","journal-title":"Crohns Colitis 360"},{"key":"2026071510051895000_16.7.e116239.9","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-07004-2","article-title":"Underrepresentation of women in randomized controlled trials: a systematic review and meta-analysis","volume":"23","author":"Daitch","year":"2022","journal-title":"Trials"},{"key":"2026071510051895000_16.7.e116239.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.5202","article-title":"Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering Therapies: A Systematic Review","volume":"3","author":"Khan","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026071510051895000_16.7.e116239.11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamacardio.2023.2098","article-title":"Enrollment of Older Patients, Women, and Racial and Ethnic Minority Individuals in Valvular Heart Disease Clinical Trials: A Systematic Review","volume":"8","author":"Reddy","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026071510051895000_16.7.e116239.12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamacardio.2020.0359","article-title":"Enrollment of Older Patients, Women, and Racial\/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review","volume":"5","author":"Tahhan","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026071510051895000_16.7.e116239.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-020-01954-5","article-title":"A systematic review assessing the under-representation of elderly adults in COVID-19 trials","volume":"20","author":"Prendki","year":"2020","journal-title":"BMC Geriatr"},{"key":"2026071510051895000_16.7.e116239.14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11060-024-04769-1","article-title":"Ethnicity in neuro-oncology research: How are we doing and how can we do better?","volume":"170","author":"Baig Mirza","year":"2024","journal-title":"J Neurooncol"},{"key":"2026071510051895000_16.7.e116239.15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/cts.13513","article-title":"Sex, racial, and ethnic diversity in clinical trials","volume":"16","author":"B\u00f8ttern","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2026071510051895000_16.7.e116239.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04613-7","article-title":"Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process","volume":"21","author":"Witham","year":"2020","journal-title":"Trials"},{"key":"2026071510051895000_16.7.e116239.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2018.11.002"},{"key":"2026071510051895000_16.7.e116239.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103520"},{"key":"2026071510051895000_16.7.e116239.19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamaoncol.2023.6565","article-title":"Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access","volume":"10","author":"Underhill","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026071510051895000_16.7.e116239.20","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-019-00006-4"},{"key":"2026071510051895000_16.7.e116239.21","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15205"},{"key":"2026071510051895000_16.7.e116239.22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s43441-023-00540-2","article-title":"Applying Systems Thinking to Inform Decentralized Clinical Trial Planning and Deployment","volume":"57","author":"Betcheva","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"2026071510051895000_16.7.e116239.23","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1081150","article-title":"Decentralized clinical trials (DCTs): A few ethical considerations","volume":"10","author":"Petrini","year":"2022","journal-title":"Front Public Health"},{"key":"2026071510051895000_16.7.e116239.24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40615-016-0285-1","article-title":"Racial Differences Among Factors Associated with Participation in Clinical Research Trials","volume":"4","author":"Kurt","year":"2017","journal-title":"J Racial Ethn Health Disparities"},{"key":"2026071510051895000_16.7.e116239.25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s40615-017-0452-z","article-title":"Impact of Race Versus Education and Race Versus Income on Patients\u2019 Motivation to Participate in Clinical Trials","volume":"5","author":"Kurt","year":"2018","journal-title":"J Racial Ethn Health Disparities"},{"key":"2026071510051895000_16.7.e116239.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07780-2"},{"key":"2026071510051895000_16.7.e116239.27","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70070","article-title":"What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?","volume":"17","author":"Kopanz","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026071510051895000_16.7.e116239.28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-107737","article-title":"Do people prefer to take part in a clinical trial from home or come to site? A discrete choice experiment in type 2 diabetes mellitus","volume":"15","author":"Kopanz","year":"2025","journal-title":"BMJ Open"},{"key":"2026071510051895000_16.7.e116239.29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"2026071510051895000_16.7.e116239.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"2026071510051895000_16.7.e116239.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"2026071510051895000_16.7.e116239.32","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2.4.319"},{"key":"2026071510051895000_16.7.e116239.33","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0734-2"},{"key":"2026071510051895000_16.7.e116239.34","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-016-0232-7"},{"key":"2026071510051895000_16.7.e116239.35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.rdc.2018.01.009","article-title":"Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete Choice Experiments","volume":"44","author":"Hazlewood","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"2026071510051895000_16.7.e116239.36","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826080-00004"},{"key":"2026071510051895000_16.7.e116239.37","doi-asserted-by":"crossref","unstructured":"Ryan M , Gerard K , Amaya-Amaya M . Using Discrete Choice Experiments to Value Health and Health Care. Dordrecht, The Netherlands: Springer, 2008.","DOI":"10.1007\/978-1-4020-5753-3"},{"key":"2026071510051895000_16.7.e116239.38","unstructured":"ChoiceMetrics . Ngene 1.4 user manual and reference guide - the cutting edge in experimental design. 2024. Available: www.choice-metrics.com [Accessed 20 Oct 2025]."},{"key":"2026071510051895000_16.7.e116239.39","first-page":"588","article-title":"Brief questions to identify patients with inadequate health literacy","volume":"36","author":"Chew","year":"2004","journal-title":"Fam Med"},{"key":"2026071510051895000_16.7.e116239.40","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0520-5"},{"key":"2026071510051895000_16.7.e116239.41","doi-asserted-by":"publisher","DOI":"10.1080\/10810730.2011.604383"},{"key":"2026071510051895000_16.7.e116239.42","doi-asserted-by":"publisher","DOI":"10.1007\/S40273-024-01431-6"},{"key":"2026071510051895000_16.7.e116239.43","unstructured":"Orme BK . Getting started with conjoint analysis, strategies for product design and pricing research. Second edition. Research Publishers LLC, 2010."},{"key":"2026071510051895000_16.7.e116239.44","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-015-0118-z"},{"key":"2026071510051895000_16.7.e116239.45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/1536867X1301300312","article-title":"lclogit: A Stata Command for Fitting Latent-Class Conditional Logit Models via the Expectation-Maximization Algorithm","volume":"13","author":"Pacifico","year":"2013","journal-title":"Stata J"},{"key":"2026071510051895000_16.7.e116239.46","doi-asserted-by":"crossref","unstructured":"Hensher DA , Rose JM , Greene WH . Latent class models. In: Applied Choice Analysis. Cambridge University Press, 2015: 706\u201341.","DOI":"10.1017\/CBO9781316136232.020"},{"key":"2026071510051895000_16.7.e116239.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0191-2615(02)00046-2"},{"key":"2026071510051895000_16.7.e116239.48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jocm.2016.09.005","article-title":"Dummy coding vs effects coding for categorical variables: Clarifications and extensions","volume":"21","author":"Daly","year":"2016","journal-title":"J Choice Model"},{"key":"2026071510051895000_16.7.e116239.49","doi-asserted-by":"publisher","DOI":"10.1002\/hec.984"},{"key":"2026071510051895000_16.7.e116239.50","unstructured":"PRO EDI . PRO EDI participant characteristics table 22\/3\/2024. Available: https:\/\/www.trialforge.org\/trial-diversity\/pro-edi-improving-how-equity-diversity-and-inclusion-is-handled-in-evidence-synthesis [Accessed 13 Sep 2025]."},{"key":"2026071510051895000_16.7.e116239.51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","article-title":"A Guide to Measuring and Interpreting Attribute Importance","volume":"12","author":"Gonzalez","year":"2019","journal-title":"Patient"},{"key":"2026071510051895000_16.7.e116239.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.10.017"},{"key":"2026071510051895000_16.7.e116239.53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.seminoncol.2022.09.004","article-title":"Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action","volume":"49","author":"Pala","year":"2022","journal-title":"Semin Oncol"},{"key":"2026071510051895000_16.7.e116239.54","doi-asserted-by":"publisher","DOI":"10.1093\/eurjcn\/zvad048"},{"key":"2026071510051895000_16.7.e116239.55","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.043594"},{"key":"2026071510051895000_16.7.e116239.56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13749","article-title":"Analysis of Female Enrollment and Participant Sex by Burden of Disease in US Clinical Trials Between 2000 and 2020","volume":"4","author":"Steinberg","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026071510051895000_16.7.e116239.57","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1044\/2022_AJA-21-00244","article-title":"Race\/Ethnicity, Gender, and Socioeconomic Status Representation in U.S.-Based Randomized Controlled Trials of Tinnitus: A Systematic Review","volume":"31","author":"Deshpande","year":"2022","journal-title":"Am J Audiol"},{"key":"2026071510051895000_16.7.e116239.58","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-021-03273-1"},{"key":"2026071510051895000_16.7.e116239.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.06.022"},{"key":"2026071510051895000_16.7.e116239.60","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-12-25","article-title":"Reasons for and against participation in studies of medicinal therapies for women with breast cancer: a debate","volume":"12","author":"Luschin","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2026071510051895000_16.7.e116239.61","article-title":"Representation of women in heart failure clinical trials: Barriers to enrollment and strategies to close the gap","volume":"13","author":"Reza","year":"2022","journal-title":"Am Heart J Plus"},{"key":"2026071510051895000_16.7.e116239.62","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2034"},{"key":"2026071510051895000_16.7.e116239.63","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000773","article-title":"Gender and sex disparity in cancer trials","volume":"5","author":"Lee","year":"2020","journal-title":"ESMO Open"},{"key":"2026071510051895000_16.7.e116239.64","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-018-2667-7","article-title":"Sex and cardiovascular disease status differences in attitudes and willingness to participate in clinical research studies\/clinical trials","volume":"19","author":"Gruca","year":"2018","journal-title":"Trials"},{"key":"2026071510051895000_16.7.e116239.65","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2024.101283","article-title":"Influences on clinical trial participation: Enhancing recruitment through a gender lens - A scoping review","volume":"38","author":"Hawke","year":"2024","journal-title":"Contemp Clin Trials Commun"},{"key":"2026071510051895000_16.7.e116239.66","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-14-1156","article-title":"Impact of gender on the decision to participate in a clinical trial: a cross-sectional study","volume":"14","author":"Lobato","year":"2014","journal-title":"BMC Public Health"},{"key":"2026071510051895000_16.7.e116239.67","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s11883-022-01064-0","article-title":"Best Practices for Designing Informative Trials Including Women","volume":"24","author":"Nicolas","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"2026071510051895000_16.7.e116239.68","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-023-02408-w","article-title":"Strategies for enhancing the representation of women in clinical trials: an evidence map","volume":"13","author":"Goldstein","year":"2024","journal-title":"Syst Rev"},{"key":"2026071510051895000_16.7.e116239.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2024.12.011"},{"key":"2026071510051895000_16.7.e116239.70","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00404-018-4886-2","article-title":"Participation of elderly gynecological cancer patients in clinical trials","volume":"298","author":"Prieske","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"2026071510051895000_16.7.e116239.71","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15081743","article-title":"Willingness to Participate in Vaccine-Related Clinical Trials among Older Adults","volume":"15","author":"Raheja","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"2026071510051895000_16.7.e116239.72","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2022-002044","article-title":"Sociodemographic and psychological characteristics influencing patients\u2019 willingness to participate in clinical trials","volume":"11","author":"Gouveia","year":"2022","journal-title":"BMJ Open Qual"},{"key":"2026071510051895000_16.7.e116239.73","doi-asserted-by":"crossref","first-page":"101455","DOI":"10.1016\/j.arr.2021.101455","article-title":"Underrepresentation of older adults in clinical trials on COVID-19 vaccines: A systematic review","volume":"71","author":"Veronese","year":"2021","journal-title":"Ageing Res Rev"},{"key":"2026071510051895000_16.7.e116239.74","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.13876","article-title":"Under-representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database","volume":"85","author":"Ruiter","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2026071510051895000_16.7.e116239.75","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.16875"},{"key":"2026071510051895000_16.7.e116239.76","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21638"},{"key":"2026071510051895000_16.7.e116239.77","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afab147"},{"key":"2026071510051895000_16.7.e116239.78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S2213-2600(24)00327-8","article-title":"Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges","volume":"13","author":"van Boven","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026071510051895000_16.7.e116239.79","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41591-024-03323-w","article-title":"Recommendations to promote equity, diversity and inclusion in decentralized clinical trials","volume":"30","author":"Aiyegbusi","year":"2024","journal-title":"Nat Med"},{"key":"2026071510051895000_16.7.e116239.80","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jamaoto.2022.1028","article-title":"Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020: A Systematic Review","volume":"148","author":"Sauer","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2026071510051895000_16.7.e116239.81","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurjpc\/zwad030","article-title":"Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis","volume":"30","author":"Sawant","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026071510051895000_16.7.e116239.82","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/jsxmed\/qdaf134","article-title":"Diversity matters in Peyronie\u2019s disease clinical trials-a systematic review","volume":"22","author":"Mass Lindenbaum","year":"2025","journal-title":"J Sex Med"},{"key":"2026071510051895000_16.7.e116239.83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030019","article-title":"Are racial and ethnic minorities less willing to participate in health research?","volume":"3","author":"Wendler","year":"2006","journal-title":"PLoS Med"},{"key":"2026071510051895000_16.7.e116239.84","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40615-016-0280-6","article-title":"Exploring Willingness to Participate in Clinical Trials by Ethnicity","volume":"4","author":"Pariera","year":"2017","journal-title":"J Racial Ethn Health Disparities"},{"key":"2026071510051895000_16.7.e116239.85","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1080\/10810730.2015.1018599","article-title":"Barriers to Clinical Trial Participation: Comparing Perceptions and Knowledge of African American and White South Carolinians","volume":"20","author":"Kim","year":"2015","journal-title":"J Health Commun"},{"key":"2026071510051895000_16.7.e116239.86","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/bmb\/ldad022","article-title":"The future of clinical trials-is it virtual?","volume":"148","author":"Ng","year":"2023","journal-title":"Br Med Bull"},{"key":"2026071510051895000_16.7.e116239.87","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1441"},{"key":"2026071510051895000_16.7.e116239.88","doi-asserted-by":"crossref","DOI":"10.1186\/s12910-025-01211-7","article-title":"Diversity in decentralized clinical trials: prioritizing inclusion of underrepresented groups","volume":"26","author":"van Rijssel","year":"2025","journal-title":"BMC Med Ethics"},{"key":"2026071510051895000_16.7.e116239.89","doi-asserted-by":"crossref","first-page":"106740","DOI":"10.1016\/j.cct.2022.106740","article-title":"Inclusion and diversity in clinical trials: Actionable steps to drive lasting change","volume":"116","author":"Kelsey","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"2026071510051895000_16.7.e116239.90","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-025-08769-y","article-title":"Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review","volume":"26","author":"Alarc\u00f3n Garavito","year":"2025","journal-title":"Trials"},{"key":"2026071510051895000_16.7.e116239.91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mpr.1434","article-title":"Barriers to recruiting ethnic minorities to mental health research: a systematic review","volume":"23","author":"Brown","year":"2014","journal-title":"Int J Methods Psych Res"},{"key":"2026071510051895000_16.7.e116239.92","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41366-024-01545-z","article-title":"A systematic review of recruitment and retention of ethnic minorities and migrants in obesity prevention randomised controlled trials","volume":"48","author":"Wali","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"2026071510051895000_16.7.e116239.93","unstructured":"Eurostat . Digital economy and society statistics - households and individuals. Available: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Digital_economy_and_society_statistics_-_households_and_individuals [Accessed 13 Sep 2025]."},{"key":"2026071510051895000_16.7.e116239.94","unstructured":"Eurostat . Eurostat regional yearbook 2024 edition. Available: https:\/\/ec.europa.eu\/eurostat\/web\/products-flagship-publications\/w\/ks-ha-24-001 [Accessed 13 Sep 2025]."},{"key":"2026071510051895000_16.7.e116239.95","unstructured":"Eurostat . Urban-rural europe - demographic developments in cities. Available: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Urban-rural_Europe_-_demographic_developments_in_cities [Accessed 13 Sep 2025]."},{"key":"2026071510051895000_16.7.e116239.96","unstructured":"IQVIA, EFPIA-VE . Assessing the clinical trial ecosystem in europe \u2013 final report. Available: https:\/\/efpia.eu\/media\/3edpooqp\/assessing-the-clinical-trial-ecosystem-in-europe.pdf [accessed 13 Sep 2025]"},{"key":"2026071510051895000_16.7.e116239.97","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/DMSO.S445288","article-title":"Type 2 Diabetes, the Epidemic: Trends in Prevalence and Incidence, 2004-2020","volume":"17","author":"Overbeek","year":"2024","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-116239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:06:11Z","timestamp":1784135171000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-116239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":97,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2026-116239"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-116239","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}